secwatch.observer — SEC 8-K summary
======================================

Issuer:     Harvard Apparatus Regenerative Technology, Inc. (HRGN)
CIK:        0001563665
Form:       8-K
Filed at:   2023-04-06T23:59:59+00:00
Accession:  0001493152-23-011145
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01, 3.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biostage raises ~$6M via private placement of 1M shares at $6.00; preferred stock converted
--------------------------------------------------------------------------------

- Gross proceeds ~$6M from sale of 1,000,967 shares at $6.00/share; $3.6M received by Apr 5, 2023.
- Funds to accelerate clinical trial of Biostage Esophageal Implant (BEI) for esophageal cancer/injury.
- All Series E Preferred Stock plus accrued dividends will convert to ~675,000 common shares at $6.00, eliminating Series E.
- FDA approved 10-patient Phase 1/2 trial for BEI; potential expansion to pediatric and bronchial indications.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1563665/000149315223011145/0001493152-23-011145-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1563665/000149315223011145/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-011145

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer